On September 5th, the FDA released 89 new complete response letters (CRLs) that had been sent to pharmaceutical manufacturers in 2024 and 2025. The release of these letters, indicating that the FDA cannot approve the drug maker’s product at the present time, were part of the agency’s transparency initiative that we reported on in July. … Continue reading The Latest Biosimilar-Related Complete Response Letters Released by FDA